All News

Phase 2 TRAPEDS-1 trial data show tralokinumab produced consistent pharmacokinetics and tolerability in children aged 6 to 11 years with moderate-to-severe atopic dermatitis.

Catch up on the 7 FDA drug approvals most relevant to primary care, including new options for hypertension, weight management, acne, and more.

FDA approval makes Differin Epiduo Acne Gel available OTC for patients aged 12 years or older with acne.

Clinicians discuss DKA risk, sick day plans, CGM use, and ketone testing in primary care.

Eden Miller, DO, and panelists discuss DKA recognition gaps, ketone testing barriers, and the future of dual glucose-ketone sensing.

The FDA recently approved the first generic baloxavir tablet for influenza treatment and postexposure prophylaxis in patients aged 5 years or older.

SLEEP 2026: A sleep expert discusses screening tools, referral pathways, and why sleep disorders matter for cardiometabolic health in primary care.

CGM prescribing in primary care was associated with lower HbA1c levels, fewer hospitalizations, and fewer ED visits among insulin-treated adults.

A primary care telehealth mindfulness program improved chronic low back pain and pain interference through 12 months in OPTIMUM.

A 10-week video-based cognitive rehabilitation program improved patient-set goals in adults with long COVID cognitive symptoms.

Recent FDA actions include updates on COVID-19 prophylaxis, ADHD, PTSD neuromodulation, and pediatric psoriasis and psoriatic arthritis care.

FDA approved roflumilast (Zoryve) cream 0.3% for plaque psoriasis in children as young as age 2, expanding the once-daily steroid-free topical indication.

A deep learning ECG model identified a high-risk group with a 7.0% annual sudden cardiac death rate in a new study.

FDA approved risankizumab for children aged 6 years or older with moderate to severe plaque psoriasis or active psoriatic arthritis.

Centanafadine XR improved adult ADHD symptoms in a phase 3b trial of patients with comorbid generalized or social anxiety disorder.

SLEEP 2026: Ashesha Mechineni, MD, discusses what the emerging pharmacotherapy pipeline means for clinicians.

Tirzepatide, nerve stimulation, and oral AD109 are reshaping OSA care as phenotyping replaces the one-size-fits-all CPAP default.

Survey finds 18 million women 45–64 overdue for cancer screening, led by colorectal gaps—bundled reminders could